• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症临床试验的结果指标:扩展残疾状态量表和多发性硬化症功能综合评分的相对测量精度

Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.

作者信息

Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A

机构信息

Peninsula Medical School, Derriford Hospital, Plymouth, Devon, UK.

出版信息

Mult Scler. 2004 Feb;10(1):41-6. doi: 10.1191/1352458504ms983oa.

DOI:10.1191/1352458504ms983oa
PMID:14760951
Abstract

We compared the relative measurement precision (RMP) of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) for discriminating between groups of patients known to differ in their extent of multiple sclerosis (MS). A total of 133 patients were rated with the EDSS and MSFC and had magnetic resonance imaging (MRI) scans. Patients were grouped on the basis of MRI appearances (T1- and T2-weighted lesion loads, parenchymal and ventricular fractions--T1LL, T2LL, PF, VF, respectively) and RMP was determined using the method of group differences. For each MRI parameter, the total sample was arranged in ascending order of magnitude and divided into two, three, four and five similar sized groups. For each division (two, three, four or five groups), EDSS and MSFC scores for the groups were compared using parametric (paired samples t-tests, one-way ANOVA) and nonparametric (Wilcoxon's rank-sum test, Kruskal-Wallis analysis of variance) statistical methods and RMP was estimated. The EDSS and MSFC were correlated substantially (r = -0.64). Relative to the MSFC, the EDSS had inferior measurement precision regardless of the number of groups into which the total sample was divided, or the statistical method. However, the RMP of the EDSS compared with the MSFC varied from 2% to 86%. Results suggest the MSCF is better than the EDSS for detecting differences between groups of patients, defined by these MRI markers of MS. However, the finding that both scales correlated weakly with MRI markers, indicated that they are limited as predictors of MS pathology as defined by MRI. An explanation for this well-established clinical-MRI paradox is that rating scales and MRI measure fundamentally different manifestations of MS.

摘要

我们比较了扩展残疾状态量表(EDSS)和多发性硬化功能复合量表(MSFC)在区分已知多发性硬化(MS)程度不同的患者组时的相对测量精度(RMP)。共有133例患者接受了EDSS和MSFC评分,并进行了磁共振成像(MRI)扫描。患者根据MRI表现(T1加权和T2加权病变负荷、实质和脑室分数——分别为T1LL、T2LL、PF、VF)进行分组,并使用组间差异法确定RMP。对于每个MRI参数,将总样本按大小升序排列,并分为两个、三个、四个和五个大小相似的组。对于每个划分(两组、三组、四组或五组),使用参数统计方法(配对样本t检验、单因素方差分析)和非参数统计方法(Wilcoxon秩和检验、Kruskal-Wallis方差分析)比较各组的EDSS和MSFC评分,并估计RMP。EDSS和MSFC显著相关(r = -0.64)。相对于MSFC,无论总样本分为多少组或采用何种统计方法,EDSS的测量精度都较低。然而,EDSS与MSFC相比的RMP在2%至86%之间变化。结果表明,对于检测由这些MS的MRI标记物定义的患者组之间的差异,MSCF比EDSS更好。然而,两个量表与MRI标记物的相关性较弱,这表明它们作为MRI定义的MS病理学预测指标存在局限性。对于这一公认的临床-MRI悖论的一种解释是,评分量表和MRI测量的是MS的根本不同表现。

相似文献

1
Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.多发性硬化症临床试验的结果指标:扩展残疾状态量表和多发性硬化症功能综合评分的相对测量精度
Mult Scler. 2004 Feb;10(1):41-6. doi: 10.1191/1352458504ms983oa.
2
Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.多发性硬化症患者复发治疗期间及之后,多发性硬化功能综合评分、扩展残疾状态量表与健康相关生活质量之间的相关性。
J Neurol Sci. 2004 Mar 15;218(1-2):3-7. doi: 10.1016/j.jns.2003.09.015.
3
Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.多发性硬化功能综合评分的临床意义:与患者报告的生活质量的关系。
Arch Neurol. 2000 Sep;57(9):1319-24. doi: 10.1001/archneur.57.9.1319.
4
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.多发性硬化功能综合指标:一种用于多发性硬化症试验的新临床结局测量方法。
Mult Scler. 2002 Oct;8(5):359-65. doi: 10.1191/1352458502ms845oa.
5
Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.随访中多发性硬化功能综合指标的应用:与疾病表型、残疾及治疗策略的关系
J Neurol Sci. 2005 May 15;232(1-2):65-9. doi: 10.1016/j.jns.2005.01.008.
6
Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses.扩展残疾状态量表和多发性硬化功能综合评分作为多发性硬化临床试验临床终点的评估:定量荟萃分析
Curr Med Res Opin. 2016 Dec;32(12):1969-1974. doi: 10.1080/03007995.2016.1222516. Epub 2016 Sep 7.
7
Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.低对比度字母视力测试可发现多发性硬化症患者的视觉功能障碍。
Neurology. 2005 Mar 22;64(6):992-5. doi: 10.1212/01.WNL.0000154521.40686.63.
8
Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.在多发性硬化功能复合量表(MSFC)中,符号数字模式测验(SDMT)是否应替代连续性能测验(PASAT)?一项为期5年的纵向研究。
Mult Scler. 2008 Nov;14(9):1242-9. doi: 10.1177/1352458508094398. Epub 2008 Jul 24.
9
Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.使用MRI作为生物学疾病标志物时MS功能综合评分的同时效度。
Neurology. 2001 Jan 23;56(2):215-9. doi: 10.1212/wnl.56.2.215.
10
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.扩展残疾状态量表(EDSS)和多发性硬化功能综合评分(MSFC)在原发性进行性多发性硬化中的反应性和预测价值。
Neurology. 2008 Mar 25;70(13 Pt 2):1084-91. doi: 10.1212/01.wnl.0000288179.86056.e1. Epub 2008 Jan 9.

引用本文的文献

1
Role of vitamin D as adjuvant therapy on multiple sclerosis: an updated systematic review and meta-analysis of randomized controlled trials.维生素D作为多发性硬化辅助治疗的作用:随机对照试验的最新系统评价和荟萃分析
Eur J Med Res. 2025 Aug 12;30(1):736. doi: 10.1186/s40001-025-02981-x.
2
Non-lesional white matter in relapsing-remitting multiple sclerosis assessed by multicomponent T2 relaxation.多组分 T2 弛豫评估复发缓解型多发性硬化的非病灶性脑白质。
Brain Behav. 2023 Dec;13(12):e3334. doi: 10.1002/brb3.3334. Epub 2023 Dec 2.
3
Predictive MRI Biomarkers in MS-A Critical Review.
MRI 预测生物标志物在 MS 中的应用——批判性综述。
Medicina (Kaunas). 2022 Mar 3;58(3):377. doi: 10.3390/medicina58030377.
4
Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.验证莱斯特咳嗽问卷的西班牙语版本在非囊性纤维化支气管扩张症中的应用。
Chron Respir Dis. 2016 May;13(2):128-36. doi: 10.1177/1479972316632005. Epub 2016 Feb 22.
5
Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression.复发型多发性硬化症安慰剂组中扩展残疾状态量表进展的变化:一项系统评价与Meta回归分析
PLoS One. 2015 Sep 1;10(9):e0137052. doi: 10.1371/journal.pone.0137052. eCollection 2015.
6
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.进展性多发性硬化症的临床试验:经验教训与未来展望。
Lancet Neurol. 2015 Feb;14(2):208-23. doi: 10.1016/S1474-4422(14)70264-9.
7
Development and validation of the activity significance personal evaluation (ASPEn) scale.活动意义个人评估(ASPEn)量表的开发与验证
Aust Occup Ther J. 2014 Dec;61(6):384-93. doi: 10.1111/1440-1630.12155. Epub 2014 Oct 4.
8
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.磁共振成像及临床疾病活动度在多发性硬化临床分类及病程评估中的应用:2010年3月5日至7日国际多发性硬化临床管理委员会共识会议报告
Int J MS Care. 2012 Fall;14(3):105-14. doi: 10.7224/1537-2073-14.3.105.
9
Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.多发性硬化易感性基因:与复发严重程度和恢复的关联。
PLoS One. 2013 Oct 9;8(10):e75416. doi: 10.1371/journal.pone.0075416. eCollection 2013.
10
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.那他珠单抗对继发进展型和残疾复发缓解型多发性硬化症的步行能力改善的影响。
PLoS One. 2013;8(1):e53297. doi: 10.1371/journal.pone.0053297. Epub 2013 Jan 4.